A critical review of CA 27.29 and CA 15-3 is performed in this paper. A review of the literature is undertaken. A review of the FDA submissions for 27.29 for both early stage and monitoring metastatic breast cancer patients is reviewed.
HullS.R., BrightA., CarrawayK.L., AbeM., HayesD.F., KufeD.W.Oligosaccharide differences in the DF-3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line.Cancer Commun1989; 1: 261–7.
2.
BonG., KenemansP., van KampG., YedemaC., HilgersJ.Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients.J Nucl Med Allied Sci1990; 34(Suppl. 3): 151–62.
3.
HayesD.F., SekineH., OhnoT., AbeM., KeefeK., KufeD.W.Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.J Clin Invest1985; 75: 1671–8.
4.
PriceM.R., RyeP.D., PetrakouE.Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin.Tumor Biology1998; 19(S1): 1–20.
5.
MayoJ.M., ArenaF.P.Performance of serum tumor markers in detection of metastatic breast cancer: Does lack of positive markers indicate poor prognosis?Proc Am Soc Clin Oncol1997; 16: 638 (abstract).
6.
AspesletL., BallokJ., MansbachL., MaimonisP.J.A technical and clinical evaluation of 3 commercial MUC-1 breast cancer marker assays.Tumor Biology1998; 19(S2): 13 (abstract).
7.
LeonA., MioneR., GionM.ACS: 180 BR Assay: Evaluation in primary breast cancer in comparison with CA 15.3.Tumor Biology1998; 19(S2): 65 (abstract).
8.
HouserS., MaimonisP.An analytical and clinical comparison of ACS: 180” BR’ with two other breast tumor marker assays.Clin Chem1997; 43: 1477 (abstract).
9.
ChanD.W., BeveridgeR.A., MussH.Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.J Clin Oncol1997; 15: 2322–8.
10.
HayesD.F., ZurawskiV.R.J., KufeD.W.Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer.J Clin Oncol1986; 4: 1542–50.
11.
AbbateI., CorrealeM., MusciM.D.Comparison of CA 27.29 with CA 15-3 in breast cancer.J Tumor Marker Oncol1998; 8(1): 69–72.
